Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial

被引：5

作者：

Issels, Rolf D. ^{[1
,19
]}

Boeck, Stefan ^{[1
]}

Pelzer, Uwe ^{[2
]}

Mansmann, Ulrich ^{[3
]}

Ghadjar, Pirus ^{[2
]}

Lindner, Lars H. ^{[1
]}

Albertsmeier, Markus ^{[1
]}

Angele, Martin K. ^{[1
]}

Schmidt, Michael ^{[3
]}

Xu, Yujun ^{[3
]}

Bahra, Marcus ^{[4
]}

Pratschke, Johann ^{[2
]}

Schoenberg, Michael ^{[5
]}

Thasler, Wolfgang E. ^{[5
]}

Salat, Christoph ^{[6
]}

Stoetzer, Oliver J. ^{[6
]}

Knoefel, Wolfram T. ^{[7
]}

Graf, Dirk ^{[8
]}

Wessalowski, Rudiger ^{[7
]}

Keitel-Anselmino, Verena ^{[9
]}

Koenigsrainer, Alfred ^{[10
]}

Bitzer, Michael ^{[10
]}

Zips, Daniel ^{[10
]}

Bamberg, Michael ^{[10
]}

Fietkau, Rainer ^{[11
]}

Ott, Oliver ^{[11
]}

Kawecki, Maciej ^{[12
]}

Wyrwicz, Lucian ^{[12
]}

Rutkowski, Piotr ^{[12
]}

Rentsch, Markus ^{[13
]}

Ababei, Juliana ^{[14
]}

Reichardt, Peter ^{[15
]}

Rigamonti, Marco ^{[16
]}

Weber, Bernhard ^{[17
]}

Abdel-Rahman, Sultan ^{[1
]}

Tschoep-Lechner, Katharina ^{[1
]}

Jauch, Karl-Walter ^{[1
]}

Bruns, Christiane J. ^{[18
]}

Oettle, Helmut ^{[2
]}

von Bergwelt-Baildon, Michael ^{[1
]}

Heinemann, Volker ^{[1
]}

Werner, Jens ^{[1
]}

机构：

[1] Ludwig Maximilians Univ Munchen, LMU Univ Hosp Munich, Munich, Germany

[2] Charite, Berlin, Germany

[3] Ludwig Maximilians Univ Munchen, Munich Inst Med Data Proc Biometr & Epidemiol, Munich, Germany

[4] Acad Hosp Waldfriede Charite, Berlin, Germany

[5] Red Cross Hosp Munich, Munich, Germany

[6] Munchen GmbH, Med Ctr Hematol Oncol, Munich, Germany

[7] Univ Hosp Dusseldorf, Dusseldorf, Germany

[8] Grevenbroich St Elizabeth Hosp, Rheinland Hosp Grp, Grevenbroich, Germany

[9] Univ Hosp Magdeburg, Otto Guericke Univ, Magdeburg, Germany

[10] Univ Hosp Tubingen, Tubingen, Germany

[11] Erlangen Univ Hosp, Erlangen, Germany

[12] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[13] Hosp Ingolstadt, Ingolstadt, Germany

[14] Hosp Landshut, Landshut, Germany

[15] HELIOS Hosp Berlin Buch, Berlin, Germany

[16] Red Cross Hosp Lindenberg, Lindenberg, Germany

[17] Hosp Bad Trissl, Oberaudorf, Germany

[18] Univ Hosp Cologne, Cologne, Germany

[19] Ludwig Maximilians Univ Munchen, Marchioninistr15, D-81377 Munich, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2023年 / 181卷

关键词：

Pancreatic cancer; Adjuvant chemotherapy; Randomised clinical trial; Regional hyperthermia; Cisplatin; Gemcitabine; HEAT study; SOFT-TISSUE SARCOMA; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; CANCER; MULTICENTER; THERAPY; FUTURE;

D O I：

10.1016/j.ejca.2022.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Regional hyperthermia (RHT) with cisplatin added to gemcitabine showed efficacy in gemcitabine-pre-treated patients with advanced pancreatic ductal adeno-carcinoma. We conducted a randomised clinical trial to investigate RHT with cisplatin added to gemcitabine (GPH) compared with gemcitabine (G) in the adjuvant setting of resected pancreatic ductal adenocarcinoma.Methods: This randomised, multicentre, open-label trial randomly assigned patients to either GPH (gemcitabine 1000 mg/m2 on day 1, 15 and cisplatin 25 mg/m2 with RHT on day 2, 3 and 15,16) or to G (gemcitabine 1000 mg/m2 on day 1,8,15), four-weekly over six cycles. Disease -free survival (DFS) was the primary end-point. Secondary end-points included overall survival (OS) and safety.Results: A total of 117 eligible patients (median age, 63 years) were randomly allocated to treatment (57 GPH; 60 G). With a follow-up time of 56.6 months, the median DFS was 12.7 compared to 11.2 months for GPH and G, respectively (p = 0.394). Median post -recurrence survival was significantly prolonged in the GPH-group (15.3 versus 9.8 months; p = 0.031). Median OS reached 33.2 versus 25.2 months (p = 0.099) with 5-year survival rates of 28.4% versus 18.7%. Excluding eight patients who received additional capecitabine in the G -arm (investigators choice), median OS favoured GPH (p = 0.052). Adverse events CTCAE (Common Terminology Criteria for Adverse Events) grade >3 occurred in 61.5% (GPH) versus 63.6% (G) of patients. Two patients in the G-group died because of treatment -related toxic effects.Conclusions: The randomised controlled Hyperthermia European Adjuvant Trial study failed to demonstrate a significant difference in DFS. However, it suggests a difference in post -recurrence survival and a trend for improved OS.ClinicalTrials: gov, number NCT01077427.(c) 2022 Elsevier Ltd. All rights reserved.

引用

页码：155 / 165

页数：11

共 50 条

[1] Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
Kang, Sora
Yoo, Changhoon
Lee, So Heun
Oh, Dongwook
Song, Tae Jun
Lee, Sang Soo
Jeong, Jae Ho
Park, Do Hyun
Seo, Dong Wan
Park, Jin-hong
Hwang, Dae Wook
Song, Ki Byung
Lee, Jae Hoon
Lee, Woohyung
Kwak, Bong Jun
Hong, Sarang
Chang, Heung-Moon
Ryoo, Baek-Yeol
Kim, Kyu-pyo
Kim, Song Cheol
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[2] Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma
Suzuki, Takashi
Mori, Shozo
Shimizu, Takayuki
Tago, Kazuma
Harada, Nobuhiro
Park, Kyung-Hwa
Sakuraoka, Yuhki
Shiraki, Takayuki
Iso, Yukihiro
Aoki, Taku
Kubota, Keiichi
IN VIVO, 2019, 33 (06): : 2027 - 2035
[3] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Tschoep-Lechner, Katharina Elisabeth
Milani, Valeria
Berger, Frank
Dieterle, Nelli
Abdel-Rahman, Sultan
Salat, Christoph
Issels, Rolf-Dieter
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16
[4] Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function
Tomimaru, Yoshito
Eguchi, Hidetoshi
Iwagami, Yoshifumi
Akita, Hirofumi
Noda, Takehiro
Gotoh, Kunihito
Kobayashi, Shogo
Nagano, Hiroaki
Mori, Masaki
Doki, Yuichiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 537 - 545
[5] Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
Blomstrand, Hakon
Bodarve, Malin
Groth, Fredrik
Naredi, Peter
Sund, Malin
Vilhav, Caroline
Green, Henrik
Bjornsson, Bergthor
Ohlund, Daniel
Lindblad, Stina
Franklin, Oskar
Elander, Nils O.
ONCOLOGY LETTERS, 2025, 29 (02)
[6] Chemotherapy with Gemcitabine and Cisplatin for Advanced Ductal Adenocarcinoma of the Prostate: Clinical Courses of Two Patients
Kamiyama, Yoshihiro
Mitsuzuka, Koji
Watanabe, Mika
Kawamorita, Naoki
Yamada, Shigeyuki
Kaiho, Yasuhiro
Ito, Akihiro
Nakagawa, Haruo
Arai, Yoichi
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 237 (04) : 317 - 321
[7] Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial
Shin, Dong Woo
Lee, Jong-chan
Kim, Jaihwan
Yoon, Yoo-Seok
Han, Ho-Seong
Kim, Haeryoung
Hwang, Jin-Hyeok
PANCREATOLOGY, 2021, 21 (04) : 796 - 804
[8] A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
Palmer, Daniel H.
Stocken, Deborah D.
Hewitt, Helen
Markham, Catherine E.
Hassan, A. Bassim
Johnson, Philip J.
Buckels, John A. C.
Bramhall, Simon R.
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) : 2088 - 2096
[9] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Jeffry
Steward, William P.
Palmer, Daniel
Propper, David
Venugopal, Balaji
Hategan, Mirela
Anthoney, D. Alan
Hampson, Lisa V.
Nebozhyn, Michael
Tuveson, David
Farmer-Hall, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah
Jodrell, Duncan
BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 793 - 801
[10] A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
Chao, Yee
Wu, Chen-Yi
Wang, Jack P.
Lee, Rheun-Chuan
Lee, Wei-Ping
Li, Chung-Pin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 637 - 642

← 1 2 3 4 5 →